StocksMedium•4 November 2026•
1 min read
Rhythm Pharmaceuticals Reports Positive Phase 2 Results for Bivamelagon Obesity Drug
Key Facts
1Rhythm Pharmaceuticals announced positive Phase 2 clinical trial results for bivamelagon in patients with acquired hypothalamic obesity.
2The company plans to initiate a Phase 3 clinical trial for the drug following these positive results.
Rhythm Pharmaceuticals announced positive Phase 2 clinical trial results for bivamelagon in patients with acquired hypothalamic obesity. Benzinga reported that the company plans to initiate a Phase 3 clinical trial for the drug following these successful results.
RYTM closed at $86.44 on November 3, 2026, with the stock trading between a low of $81.58 and a high of $89.28 during that session. These clinical developments represent a significant milestone for Rhythm Pharmaceuticals as the program met its objectives, providing the basis for pivotal development.